LEADER 05247nam 2200637Ia 450 001 9910876519003321 005 20200520144314.0 010 $a1-282-55040-3 010 $a9786612550409 010 $a3-527-62948-3 010 $a3-527-62949-1 035 $a(CKB)2520000000009703 035 $a(EBL)487749 035 $a(OCoLC)609856719 035 $a(SSID)ssj0000364143 035 $a(PQKBManifestationID)11263699 035 $a(PQKBTitleCode)TC0000364143 035 $a(PQKBWorkID)10393812 035 $a(PQKB)11763427 035 $a(MiAaPQ)EBC487749 035 $a(EXLCZ)992520000000009703 100 $a20071130d2010 uy 0 101 0 $aeng 135 $aur|n|---||||| 181 $ctxt 182 $cc 183 $acr 200 00$aParkinson disease $ea health policy perspective /$fedited by Wayne Martin [et al.] 210 $aWeinheim $cWiley-VCH Verlag GmbH & Co.$dc2010 215 $a1 online resource (362 p.) 225 1 $aHealth Care and Disease Management 300 $aDescription based upon print version of record. 311 $a3-527-32779-7 320 $aIncludes bibliographical references and index. 327 $aParkinson Disease: A Health Policy Perspective; Contents; Preface; Summary and Policy Considerations; List of Contributors; Part I: Parkinson Disease - Diagnosis and Treatment; 1: Parkinson Disease; 1.1: Patient Burden; 1.2: Characteristics of Parkinson Disease; 1.3: Diagnosis of Parkinson Disease; 1.4: Treatment for Parkinson Disease; References; 2: Clinical Features of Parkinson Disease; 2.1: Introduction; 2.2: Cardinal Features; 2.3: Differential Diagnosis; 2.3.1: Essential Tremor; 2.3.2: Progressive Supranuclear Palsy; 2.3.3: Multiple System Atrophy 327 $a2.3.4: Cortico-Basal Ganglionic Degeneration2.3.5: Dementia with Lewy Bodies; 2.3.6: Vascular Parkinsonism; 2.4: Non-Dopaminergic Features of PD; 2.4.1: Sleep Disturbances; 2.4.2: Olfaction; 2.4.3: Dysautonomia; 2.4.4: Neuropsychiatric Features; 2.4.4.1: Dementia; 2.4.4.2: Depression; 2.5: Natural History; 2.6: Conclusions; References; 3: Current Approaches to the Management of Parkinson Disease; 3.1: Introduction; 3.2: Pharmacologic Treatment; 3.2.1: Symptomatic Therapy; 3.2.1.1: Levodopa; 3.2.1.2: Levodopa-Induced Motor Complications; 3.2.1.3: Catechol-O-Methyl Transferase (COMT) Inhibitors 327 $a3.2.1.4: Monoamine Oxidase B (MAO-B) Inhibitors3.2.1.5: Dopamine Agonists; 3.2.1.6: Managing Drug-Induced Adverse Events; 3.2.2: Neuroprotective Therapy; 3.2.3: Surgical Treatment; 3.2.4: Non-Pharmacologic Treatment; 3.3: Nursing; 3.4: Rehabilitation; 3.4.1: Physical Therapy; 3.4.2: Occupational Therapy; 3.4.3: Speech Therapy; 3.5: Nutrition; 3.6: Psychosocial Issues; 3.7: Conclusions; References; 4: Treatment of Non-Motor Symptoms of Parkinson Disease; 4.1: Sleep Disturbances; 4.2: Autonomic Dysfunction; 4.2.1: Orthostatic (Postural) Hypotension; 4.2.2: Urinary Dysfunction 327 $a4.2.3: Gastrointestinal Dysfunction4.2.3.1: Dysphagia; 4.2.3.2: Gastroparesis; 4.2.3.3: Constipation; 4.2.3.4: Anorectal Dysfunction; 4.2.4: Weight Loss; 4.2.5: Sweating Disturbances; 4.2.6: Sexual Dysfunction; 4.2.7: Sialorrhea; 4.2.8: Dyspnea; 4.3: Neuropsychiatric Problems; 4.3.1: Depression; 4.3.2: Anxiety; 4.3.3: Apathy; 4.3.4: Medication-Related Psychiatric Problems; 4.3.5: Impulse Control Disorders; 4.3.6: Dopamine Dysregulation Syndrome; 4.3.7: Punding Behavior; 4.3.8: Hypersexuality; 4.3.9: Dementia; 4.3.10: Psychosis; 4.4: Sensory Symptoms and Pain; 4.4.1: Pain 327 $a4.4.2: Olfactory Dysfunction4.5: Other Problems; 4.5.1: Eye Movement Abnormalities; 4.5.2: Fatigue; 4.6: Non-Motor Fluctuations; 4.7: Conclusions; References; 5: Palliative Care and End-of-Life Issues with Parkinson Disease; 5.1: Challenges in Advanced-Stage PD; 5.2: The Most Common Causes of Death in PD; 5.3: Specific Problems in the Advanced-PD Patient; 5.3.1: Pain; 5.3.2: Cognitive Decline; 5.3.3: Other Psychiatric Complications; 5.3.4: Speech and Swallowing Difficulties; 5.3.5: Bowel and Bladder Dysfunction; 5.3.6: Sleep Disturbances; 5.4: Caregiver Burden 327 $a5.4.1: Placement in Long-Term Care Facilities 330 $aPart of the successful Institute of Health Economics (IHE) book series, this handbook and ready reference adopts a unique approach in combining policy recommendations with specific treatment options for Parkinson patients.The first part of the book deals with the clinical medical, social and economical aspects of Parkinson Disease. These ten chapters include the latest diagnosis and treatment options for patients, the economical consequences, social and ethical implications and end-of life issues. The second part of the book essentially covers a large-scale case study on Parkinson in Alber 410 0$aHealth Care and Disease Management 606 $aParkinson's disease 606 $aMedical policy 615 0$aParkinson's disease. 615 0$aMedical policy. 676 $a616.833 676 $a616.83306 701 $aMartin$b Wayne$01761960 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910876519003321 996 $aParkinson disease$94201665 997 $aUNINA